196 related articles for article (PubMed ID: 23278369)
21. Medicare part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007.
Briesacher BA; Zhao Y; Madden JM; Zhang F; Adams AS; Tjia J; Ross-Degnan D; Gurwitz JH; Soumerai SB
Med Care; 2011 Sep; 49(9):834-41. PubMed ID: 21544002
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of statin utilization and adherence among privately insured subjects in the Commonwealth of Puerto Rico.
Hernández-Muñoz JJ; Wong ES; Kamdar CR
J Manag Care Spec Pharm; 2021 Mar; 27(3):392-398. PubMed ID: 33645248
[No Abstract] [Full Text] [Related]
23. Effects of an out-of-pocket maximum in Medicare Part D.
Parasrampuria S; Anderson GF
Am J Manag Care; 2022 Feb; 28(2):e55-e62. PubMed ID: 35139297
[TBL] [Abstract][Full Text] [Related]
24. Medicare Part D roulette: potential implications of random assignment and plan restrictions.
Patel RA; Walberg MP; Woelfel JA; Amaral MM; Varu P
Medicare Medicaid Res Rev; 2013; 3(2):. PubMed ID: 24753963
[TBL] [Abstract][Full Text] [Related]
25. Does the offer of free prescriptions increase generic prescribing?
Stuart B; Hendrick F; Dougherty JS; Xu J
Am J Manag Care; 2017 Jun; 23(6):e193-e201. PubMed ID: 28817295
[TBL] [Abstract][Full Text] [Related]
26. Patterns of prescription drug expenditures and medication adherence among medicare part D beneficiaries with and without the low-income supplement.
Yala SM; Duru OK; Ettner SL; Turk N; Mangione CM; Brown AF
BMC Health Serv Res; 2014 Dec; 14():665. PubMed ID: 25526892
[TBL] [Abstract][Full Text] [Related]
27. Impact of Cost Sharing on Therapeutic Substitution: The Story of Statins in 2006.
Li P; Schwartz JS; Doshi JA
J Am Heart Assoc; 2016 Nov; 5(11):. PubMed ID: 27836822
[TBL] [Abstract][Full Text] [Related]
28. Is There a Relationship Between Part D Medication Adherence and Part C Intermediate Outcomes Star Ratings Measures?
Ta JT; Erickson SC; Qiu WA; Patel BV
J Manag Care Spec Pharm; 2016 Jul; 22(7):787-95. PubMed ID: 27348279
[TBL] [Abstract][Full Text] [Related]
29. Utilization and costs of medications associated with CKD mineral and bone disorder in dialysis patients enrolled in Medicare Part D.
Yusuf AA; Howell BL; Powers CA; St Peter WL
Am J Kidney Dis; 2014 Nov; 64(5):770-80. PubMed ID: 24833203
[TBL] [Abstract][Full Text] [Related]
30. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
[TBL] [Abstract][Full Text] [Related]
31. How Medicare Part D benefit phases affect adherence with evidence-based medications following acute myocardial infarction.
Stuart B; Davidoff A; Erten M; Gottlieb SS; Dai M; Shaffer T; Zuckerman IH; Simoni-Wastila L; Bryant-Comstock L; Shenolikar R
Health Serv Res; 2013 Dec; 48(6 Pt 1):1960-77. PubMed ID: 23742013
[TBL] [Abstract][Full Text] [Related]
32. Out-of-pocket costs and oral cancer medication discontinuation in the elderly.
Kaisaeng N; Harpe SE; Carroll NV
J Manag Care Spec Pharm; 2014 Jul; 20(7):669-75. PubMed ID: 24967520
[TBL] [Abstract][Full Text] [Related]
33. Assessment of Trends in Statin Therapy for Secondary Prevention of Atherosclerotic Cardiovascular Disease in US Adults From 2007 to 2016.
Yao X; Shah ND; Gersh BJ; Lopez-Jimenez F; Noseworthy PA
JAMA Netw Open; 2020 Nov; 3(11):e2025505. PubMed ID: 33216139
[TBL] [Abstract][Full Text] [Related]
34. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
35. Does medication adherence lower Medicare spending among beneficiaries with diabetes?
Stuart B; Davidoff A; Lopert R; Shaffer T; Samantha Shoemaker J; Lloyd J
Health Serv Res; 2011 Aug; 46(4):1180-99. PubMed ID: 21413981
[TBL] [Abstract][Full Text] [Related]
36. Impact of an annual dollar limit or "cap" on prescription drug benefits for Medicare patients.
Tseng CW; Brook RH; Keeler E; Mangione CM
JAMA; 2003 Jul; 290(2):222-7. PubMed ID: 12851277
[TBL] [Abstract][Full Text] [Related]
37. Use of intelligent assignment to Medicare Part D plans for people with schizophrenia could produce substantial savings.
Zhang Y; Baik SH; Newhouse JP
Health Aff (Millwood); 2015 Mar; 34(3):455-60. PubMed ID: 25732496
[TBL] [Abstract][Full Text] [Related]
38. Association of Changes in Medication Use and Adherence With Accountable Care Organization Exposure in Patients With Cardiovascular Disease or Diabetes.
McWilliams JM; Najafzadeh M; Shrank WH; Polinski JM
JAMA Cardiol; 2017 Sep; 2(9):1019-1023. PubMed ID: 28700790
[TBL] [Abstract][Full Text] [Related]
39. The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility.
Liu FX; Alexander GC; Crawford SY; Pickard AS; Hedeker D; Walton SM
Health Serv Res; 2011 Aug; 46(4):1104-23. PubMed ID: 21609328
[TBL] [Abstract][Full Text] [Related]
40. Part D coverage gap reform: trends in drug use and expenditures.
Park J; Look KA
Am J Manag Care; 2020 Aug; 26(8):349-356. PubMed ID: 32835462
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]